2012 Movember Pilot Grants










Prostate Cancer Canada would like to recognize the Movember Foundation as a key funder of this program.
Prostate Cancer Canada is pleased to announce the awarding of 16 innovative Movember Pilot Grants. This year PCC received a total of 125 applications to its Movember Pilot Grant competition, representing an increase of more than 50% over the number of applications received in 2011. 

In order to decide which research projects should receive funding, each application is thoroughly reviewed by at least two cancer experts. These experts make recommendations to PCC regarding which research projects to fund. This process is called 'peer review'. The peer review process ensures that only the most meritorious research is supported. This year's successful research projects explore many different areas of prostate cancer including novel treatment therapies and the development of new tools to help better predict disease progression. 


Movember Established Investigator Pilot Grants

Investigator Host Institution Project Title Total Award Award Period
Christina Addison Ottawa Hospital Research Institute Regulation of prostate cancer metastasis and response to therapy by beta1 integrins $149,887 July 1, 2012 - December 31, 2014
Robert Bristow Princess Margaret Hospital High-throughput discovery of prostate tumour initiating cells markers for prognosis and personalized medicine  $150,000 July 1, 2012 - December 31, 2014
Michael Cox Vancouver Prostate Centre Regulation of DNA methyltransferases (DNMTs)  by Gli proteins and its effects on progression of prostate cancer  $150,000 July 1, 2012 - December 31, 2014
 Robert Day University of Sherbrooke The development of PACE4 inhibitors for novel prostate cancer therapies  $150,000 July 1, 2012 - December 31, 2014
Louis Lacombe Centre Hospitalier Universitaire de Québec - L'Hotel-Dieu de Québec Immune score as a new possible approach to predict prostate cancer outcome after prostatectomy $150,000 July 1, 2012 - December 31, 2014
Anne-Marie Mes-Masson Centre Hospitalier de l'Université de Montréal  Involvement of IKKe in castration resistance and prostate cancer progression $150,000 July 1, 2012 - December 31, 2014
 Mark Trifiro Jewish General Hospital Novel targeted abiotic therapeutics and imaging agents for prostate cancer  $149,960 July 1, 2012 - December 31, 2014
 Kishor Wasan University of British Columbia Role of SR-BI-mediated cholesterol influx and intercellular synthesis as potential sources of cholesterol required for de novo steroidogenesis in castration-resistant prostate cancer  $120,000 July 1, 2012 - June 30, 2014
 Gang Zheng University Health Network Porphysome-enabled focal laser ablation of prostate cancer  $150,000
 
July 1, 2012 - December 31, 2014

Movember New Investigator Pilot Grants
   
Investigator Host Institution Project Title Total Award Award Period
Alison Allan University of Western Ontario Circulating tumour cells (CTCs) in prostate cancer: are we finding the real "bad guys"? $149,758 July 1, 2012 - December 31, 2014
Hon Leong London Health Sciences Centre Non-invasive staging of prostate cancer: detection of circulating prostate microparticles using unique metastasis-specific antibody 1A5 $150,000 July 1, 2012 - December 31, 2014
Paulo Nuin Queen's University Meta-analysis of prognostic DNA copy number biomarkers for selection of unique combinations of FISH probes that correlate with aggressive CaP $150,000 July 1, 2012 - December 31, 2014
Paul Park Queen's University EMT-associated genes as prognostic biomarkers in Gleason score 3+3 biopsies of prostatic adenocarcinoma $150,000 July 1, 2012 - December 31, 2014
Frédéric Pouliot Laval University In vivo prostate cancer transcriptional signature detection using integrative multigenic molecular imaging $150,000 July 1, 2012 - December 31, 2014
John Stagg Centre de Recherche du  Centre Hospitalier de l'Université de Montréal Targeting CD73 for treatment of prostate cancer $150,000 July 1, 2012 - December 31, 2014
Amina Zoubeidi Vancouver Prostate Centre Persistent androgen receptor activation after maximum androgren blockade $150,000 July 1, 2012 - December 31, 2014
More information about these programs.    









































Support PSA Tests


Subscribe to our free monthly e-newsletter!

* indicates required

 



PCC Spotlight
Prostate Cancer Canada reminds men that early detection using ‘Smart Screening’ for prostate cancer

Toronto, ON – October 27, 2014 – Prostate Cancer Canada responds today to guidelines released from The Canadian Task Force on Preventive Health Care (CTFPHC) recommending that the Prostate Specific Antigen (PSA) test should be eliminated as a screening tool for prostate cancer. More

Prostate Cancer Canada fundraiser to donate 50% of proceeds to families of fallen soldiers

TORONTO, ON, October 24, 2014 – Following the death of two Canadian soldiers, Prostate Cancer Canada will donate half of the net proceeds raised by the Pants Off for Prostate Cancer Ottawa fundraising event, presented by Alterna Savings, to the Stand On Guard fund. More


Click here for news archive